TOKYO -- Fujifilm Holdings has joined hands with German drugmaker Bayer to develop an immune-based cancer treatment using induced pluripotent stem cells.
Currently, stem cell treatments are expensive and take time to prescribe. The Japan-German alliance intends to surmount these hurdles by using a new method in which iPS cells come from someone other than the patient. In the conventional method, cells from patients themselves are used.
